Faron Pharmaceuticals has appointed Dr. Juhana Heinonen as Chief Commercial Officer to join the company in January 2018.
Dr Heinonen joins Faron from AstraZeneca where he served as the Global Marketing Director for AstraZeneca/Medimmune’s Fasenra (benralizumab) for the treatment of asthma, the first biologic medication launched from the AstraZeneca respiratory unit.
Dr Markku Jalkanen, CEO of Faron, has welcomed Dr Heinonen saying that he has a wealth of expertise in the commercialisation and marketing of blockbuster drugs, and will be a key addition to the Faron team in preparations to enter commercialisation. “We look forward to benefitting from his experience and valuable insights as our wholly-owned lead product, Traumakine, approaches the completion of its pivotal Phase III INTEREST trial,” said Jalkanen.